针对亨廷顿病患者的有效住房和支持模式:一个范围审查
Lee Cubis1,2, Elise Davis2, Sharyn McDonald1
1Summer Foundation Ltd, Melbourne, Australia.
Journal of Huntington's disease
|October 17, 2025
概括
针对亨廷顿病 (HD) 患者的有效住房和支持模式尚未得到充分研究. 根据HD患者的不同需求,定制,灵活的支持至关重要.
科学领域:
- 神经学 神经学
- 老年学是一门学科.
- 医疗保健服务研究 医疗服务研究
背景情况:
- 亨廷顿病 (HD) 呈现出复杂的身体,认知和精神症状.
- 这些表现往往导致HD个体不适当的住房情况.
- 需要了解这种人群的有效住房和支持模式.
研究的目的:
- 对现有关于住房和支持亨廷顿病患者模式的文学进行范围审查.
- 确定对挑战的初步见解以及住房和支持患有HD的个人的有效策略.
主要方法:
- 在五个主要数据库 (MEDLINE,CINAHL,SCOPUS,PsycINFO,EMBASE) 进行系统搜索.
- 包括报告有关HD患者住房和支持模式的定性和/或定量发现的研究.
- 整合了八项资格研究的关键发现.
主要成果:
- 没有研究直接评估了HD患者住房和支持模式的有效性.
- 在获得适当的住房和支持方面发现了挑战.
- 强调需要受过培训的员工提供优质的残疾和健康支持.
- 那些有行为问题,身体健康不佳或心理社会问题的人更有可能被安置在住院养老院.
- 积极的行为支持和护理人员支持是重要的考虑因素.
结论:
- 对亨廷顿病的有效住房和支持模型的研究有限.
- 单一的最佳实践模型是不太可能的,因为HD的个体变化.
- 住房和支持策略必须灵活和个性化.
相关概念视频
Documentation in Long-Term and Home Healthcare Setting
1.4K
Documentation in long-term care facilities and home healthcare settings is crucial for ensuring continuous, coordinated, and comprehensive care for patients. Each setting has its specific documentation processes and tools:
Long-Term Care Facilities
Long-Term Care Facilities
1.4K
Parkinson's Disease: Treatment
972
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
972
Alzheimer's Disease: Treatment
811
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
811
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Methods of Documentation VI: Case Management Model
854
The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic...
For example, a patient with a chronic...
854
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K


